AGREE criteria | KNGF (previous) | KNGF (update) |
---|---|---|
1. The overall objective(s) of the guideline is (are) specifically described. | + | + |
2. The clinical question(s) covered by the guideline is (are) specifically described. | + | + |
3. The patients to whom the guideline is meant to apply are specifically described. | + | + |
4. The guideline development group includes individuals from all the relevant professional groups. | + | + |
5. The patients' views and preferences have been sought. | + | + |
6. The target users of the guideline are clearly defined. | + | + |
7. The guideline has been piloted among target users. | - | - |
8. Systematic methods were used to search for evidence. | + | + |
9. The criteria for selecting the evidence are clearly described. | + | + |
10. The methods used for formulating the recommendations are clearly described. | - | + |
11. The health benefits, side effects and risks have been considered in formulating the recommendations. | - | + |
12. There is an explicit link between the recommendations and the supporting evidence. | - | + |
13. The guideline has been externally reviewed by experts prior to its publication. | + | + |
14. A procedure for updating the guideline is provided. | - | + |
15. The recommendations are specific and unambiguous. | - | + |
16. The different options for management of the condition are clearly presented. | + | + |
17. Key recommendations are easily identifiable. | - | + |
18. The guideline is supported with tools for application. | + | + |
19. The potential organizational barriers in applying the recommendations have been discussed. | + | + |
20. The potential cost implications of applying the recommendations have been considered. | - | + |
21. The guideline presents key review criteria for monitoring and/or audit purposes. | - | + |
22. The guideline is editorially independent from the funding body. | + | + |
23. Conflicts of interest of guideline development members have been recorded. | - | + |